Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

BACKGROUND: The current expert view of the PCSK9 inhibitors’ use in Egypt is still ambiguous. MAIN BODY: Hyperlipidemia is an important, if not the most important, risk factor for the occurrence of atherosclerosis worldwide. Egypt is the most populous country in the Middle East and North Africa and...

Descripción completa

Detalles Bibliográficos
Autores principales: Reda, Ashraf, Elserafy, Ahmed Shawky, Farag, Elsayed, Mostafa, Tamer, Farag, Nabil, Elbahry, Atef, Sanad, Osama, Bendary, Ahmed, Elkersh, Ahmed, Selim, Mohammed, Beshay, Morad, Khamis, Hazem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235146/
https://www.ncbi.nlm.nih.gov/pubmed/32424543
http://dx.doi.org/10.1186/s43044-020-00058-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235146/
https://www.ncbi.nlm.nih.gov/pubmed/32424543
http://dx.doi.org/10.1186/s43044-020-00058-0

Ejemplares similares